Further concerns derive from the notion that AML biology is characterized by the subsequent emergence of multiple resistant subclones; for this reason, AML is generally treated with multidrug therapies, whether chemotherapy-based (polychemotherapy) or non-chemotherapy-based (e.g., hypomethylating agents + bcl2 inhibitors). This evidence concerns the gene BCL2 and acute myeloid leukemia.